Eris Lifesciences · NSE: ERIS · BSE: 540596
Q3 FY24 results · Oct–Dec 2023
Eris Lifesciences reported revenue from operations of ₹486.30 crore (up 14.9% from Q3 FY23) and net profit of ₹101.46 crore (up 1.2% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 486.30 | 423.26 | +14.9% | 505.30 | −3.8% |
| Other income | 4.20 | 2.24 | +87.6% | 3.48 | +20.6% |
| Total income | 490.49 | 425.50 | +15.3% | 508.78 | −3.6% |
| Profit before tax | 115.87 | 106.54 | +8.8% | 126.24 | −8.2% |
| Net profit for the period | 101.46 | 100.23 | +1.2% | 122.31 | −17.0% |
| Attributable to shareholders of the company | 102.74 | 101.86 | +0.9% | 123.43 | −16.8% |
| EPS, basic (₹) | 7.55 | 7.49 | +0.8% | 9.08 | −16.9% |
| Net margin (%) | 20.9 | 23.7 | 24.2 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 324.41 | 332.01 | −2.3% | 409.71 | −20.8% |
| Other income | 3.43 | 3.48 | −1.3% | 6.97 | −50.8% |
| Total income | 327.85 | 335.49 | −2.3% | 416.68 | −21.3% |
| Profit before tax | 34.64 | 110.23 | −68.6% | 119.92 | −71.1% |
| Net profit for the period | 31.66 | 99.38 | −68.1% | 117.81 | −73.1% |
| EPS, basic (₹) | 2.33 | 7.31 | −68.1% | 8.66 | −73.1% |
| Net margin (%) | 9.8 | 29.9 | 28.8 |
Consolidated
- Filed with BSE
- 15 Feb 2024, 10:29 IST
- Board meeting
- 13 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 Feb 2024, 10:29 IST
- Board meeting
- 13 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE